The FDA has accepted for review the BLA for nanoencapsulated sirolimus plus pegadricase in the treatment of uncontrolled gout.

Experts weigh in on the use of real-world evidence (RWE) in pain research, providing recommendations for rigorous study design, analysis, and reporting to ensure data validity and credibility.

The US Food and Drug Administration released draft guidance to advance safe and effective nonopioid treatment options and reduce risks tied to prescription opioid misuse.

Providing timely pain relief may reduce chances of hospitalization for children presenting to the emergency department with a sickle cell crisis.

For life after TBI, nurse practitioners are in a pivotal position to identify post-traumatic headache for veterans early.

A single dose of a pharmaceutical formulation of LSD provides significant relief for patients with moderate-to-severe generalized anxiety disorder (GAD).

More than half of severely injured trauma patients first treated at level III or nontrauma centers are not transferred to higher-level trauma centers.